elosulfase alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
enzymes 4999 9025-60-9

Description:

MoleculeDescription

Synonyms:

  • elosulfase alfa
  • vimizim
  • BMN 110
  • rhGALNS
  • EC 3.1.6.4
  • BMN-110
BMN-100 and BMN 110 are recombinant GALNS; RefSeq NM_000512
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
20 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 28, 2014 EMA
Feb. 14, 2014 FDA BIOMARIN PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Knee deformity 55.85 47.25 10 648 1335 63487029
Spinal cord compression 50.13 47.25 11 647 4137 63484227

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Spinal cord compression 61.70 49.61 13 360 3962 34952596

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Spinal cord compression 86.94 41.08 19 894 6358 79737117
Urticaria 63.03 41.08 34 879 185167 79558308
Knee deformity 61.87 41.08 11 902 1274 79742201
Pyrexia 51.86 41.08 50 863 678659 79064816
Oxygen saturation decreased 47.50 41.08 25 888 129022 79614453

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AB12 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Enzymes
FDA CS M0000794 alpha-Glucosidases
FDA EPC N0000175823 Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mucopolysaccharidosis, MPS-IV-A indication 7259005 DOID:0111391




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D10333 KEGG_DRUG
4033117 VUID
N0000190127 NUI
4033117 VANDF
CHEMBL2108676 ChEMBL_ID
C102295 MESH_SUPPLEMENTAL_RECORD_UI
7392 IUPHAR_LIGAND_ID
DB09051 DRUGBANK_ID
1489914 RXNORM
213108 MMSL
30194 MMSL
d08244 MMSL
015387 NDDF
702395005 SNOMEDCT_US
716640004 SNOMEDCT_US
C3817397 UMLSCUI
9686 INN_ID
ODJ69JZG85 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIMIZIM HUMAN PRESCRIPTION DRUG LABEL 1 68135-100 INJECTION, SOLUTION, CONCENTRATE 5 mg INTRAVENOUS BLA 23 sections
VIMIZIM HUMAN PRESCRIPTION DRUG LABEL 1 68135-100 INJECTION, SOLUTION, CONCENTRATE 5 mg INTRAVENOUS BLA 23 sections